{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:15:12Z","timestamp":1785899712913,"version":"3.56.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1016\/j.canlet.2005.05.021","type":"journal-article","created":{"date-parts":[[2005,7,20]],"date-time":"2005-07-20T20:08:37Z","timestamp":1121890117000},"page":"229-238","source":"Crossref","is-referenced-by-count":115,"title":["Tissue-specificity of prostate specific antigens: Comparative analysis of transcript levels in prostate and non-prostatic tissues"],"prefix":"10.1016","volume":"236","author":[{"given":"Ana C.","family":"Cunha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd","family":"Weigle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Kiessling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Peter","family":"Rieber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2003","key":"10.1016\/j.canlet.2005.05.021_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/canjclin.53.1.5","article-title":"Cancer statistics","volume":"53","author":"Jemal","year":"2003","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2005.05.021_bib2","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1056\/NEJM200105033441806","article-title":"Clinical practice Prostate-specific-antigen testing for early diagnosis of prostate cancer","volume":"344","author":"Barry","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2005.05.021_bib3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10147-003-0332-x","article-title":"Target molecules in specific immunotherapy against prostate cancer","volume":"8","author":"Harada","year":"2003","journal-title":"Int. Clin. Oncol."},{"key":"10.1016\/j.canlet.2005.05.021_bib4","first-page":"1393","article-title":"Quantification of disseminated tumor cells in the bloodstream of patients with hormone-refractory prostate carcinoma undergoing cytotoxic chemotherapy","volume":"24","author":"Schmidt","year":"2001","journal-title":"Int. J. Onc."},{"key":"10.1016\/j.canlet.2005.05.021_bib5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00001622-200305000-00007","article-title":"Prostate cancer update","volume":"15","author":"Rosenberg","year":"2003","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.canlet.2005.05.021_bib6","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/(SICI)1097-0045(19980615)36:1<39::AID-PROS6>3.0.CO;2-6","article-title":"Evaluation of phase I\/II clinical trials in prostate cancer with dendritic cells and PSMA peptides","volume":"36","author":"Tjoa","year":"1998","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2005.05.021_bib7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/(SICI)1097-0045(19990101)38:1<73::AID-PROS9>3.0.CO;2-V","article-title":"Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease","volume":"38","author":"Murphy","year":"1999","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2005.05.021_bib8","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nbt0702-659","article-title":"Therapeutic cancer vaccines on trial","volume":"20","author":"Reichert","year":"2002","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.canlet.2005.05.021_bib9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/35101072","article-title":"Improving the efficacy of antibody-based cancer therapies","volume":"1","author":"Carter","year":"2001","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2005.05.021_bib10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1535-6108(03)00057-6","article-title":"Progress in immunoconjugate cancer therapeutics","volume":"3","author":"Payne","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2005.05.021_bib11","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1126\/science.1100369","article-title":"Cancer immunotherapy: a treatment for the masses","volume":"305","author":"Blattman","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.canlet.2005.05.021_bib12","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nm0904-887","article-title":"Cancer immunotherapy: breaking the barriers to harvest the crop","volume":"10","author":"Pardoll","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2005.05.021_bib13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/pros.2990020109","article-title":"Prostate antigen: a new potential marker for prostatic cancer","volume":"2","author":"Wang","year":"1981","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2005.05.021_bib14","first-page":"319","article-title":"Immunochemical detection of serum prostatic acid phosphatase","volume":"15","author":"Chu","year":"1978","journal-title":"Invest. Urol."},{"key":"10.1016\/j.canlet.2005.05.021_bib15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ijc.11402","article-title":"Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer","volume":"107","author":"Schmittgen","year":"2003","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2005.05.021_bib16","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1158\/1078-0432.CCR-03-0200","article-title":"Detection of prostate cancer and predicting progression: current and future diagnostic markers","volume":"10","author":"Tricoli","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2005.05.021_bib17","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1073\/pnas.95.4.1735","article-title":"Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer","volume":"95","author":"Reiter","year":"1998","journal-title":"Proc. Natl Acad. Sci."},{"key":"10.1016\/j.canlet.2005.05.021_bib18","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1038\/sj.onc.1204803","article-title":"Identification of a prostate-specific G-protein coupled receptor in prostate cancer","volume":"20","author":"Xia","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2005.05.021_bib19","first-page":"6568","article-title":"PSGR a, novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer","volume":"60","author":"Xu","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2005.05.021_bib20","first-page":"1563","article-title":"Reed, Identification and characterization of prostein, a novel prostate-specific protein","volume":"61","author":"Xu","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2005.05.021_bib21","first-page":"3760","article-title":"Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares homology with transient receptor potential calcium channel proteins","volume":"6","author":"Tsavaler","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2005.05.021_bib22","first-page":"721","article-title":"AIbZIP, a novel bZIP gene located on chromosome 1q21.3 that is highly expressed in prostate tumors and of which the expression is up-regulated by androgens in LNCaP human prostate cancer cells","volume":"62","author":"Qi","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2005.05.021_bib23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/BF02700015","article-title":"Brain tumor immunotherapy: an immunologist's prespective","volume":"64","author":"Lampson","year":"2003","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.canlet.2005.05.021_bib24","first-page":"6451","article-title":"Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine","volume":"61","author":"Banchereau","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2005.05.021_bib25","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/89863","article-title":"Dendritic cells: on the move from bench to bedside","volume":"7","author":"Nestle","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2005.05.021_bib26","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/00002371-200309000-00006","article-title":"Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma","volume":"26","author":"Palucka","year":"2003","journal-title":"J. Immunother."},{"key":"10.1016\/j.canlet.2005.05.021_bib27","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2165\/00063030-200317020-00005","article-title":"Prostate cancer: advances in immunotherapy","volume":"17","author":"Hurwitz","year":"2003","journal-title":"Biodrugs"},{"key":"10.1016\/j.canlet.2005.05.021_bib28","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/sj.bjc.6602019","article-title":"A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer","volume":"91","author":"Pavlenko","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2005.05.021_bib29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/(SICI)1097-0045(19970201)30:2<73::AID-PROS1>3.0.CO;2-L","article-title":"Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen","volume":"30","author":"Xue","year":"1997","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2005.05.021_bib30","doi-asserted-by":"crossref","first-page":"3186","DOI":"10.4049\/jimmunol.161.6.3186","article-title":"Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide","volume":"161","author":"Correale","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2005.05.021_bib31","first-page":"5522","article-title":"Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer","volume":"60","author":"Dannull","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2005.05.021_bib32","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/ijc.10713","article-title":"Prostate Stem Cell Antigen: identification of immunogenic peptides and assessment of reactive CD8+T cells in prostate cancer patients","volume":"102","author":"Kiessling","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2005.05.021_bib33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/pros.20038","article-title":"A prostate stem cell antigen-derived peptide immunogenic in HLA-A24- prostate cancer patients","volume":"60","author":"Matsueda","year":"2004","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2005.05.021_bib34","doi-asserted-by":"crossref","first-page":"7150","DOI":"10.4049\/jimmunol.167.12.7150","article-title":"Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy","volume":"167","author":"Fong","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2005.05.021_bib35","first-page":"2175","article-title":"Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer","volume":"6","author":"Burch","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2005.05.021_bib36","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0022-5347(05)65821-1","article-title":"Induction of tumor specific cytotoxic T lymphocytes in prostate cancer using prostatic acid phosphatase derived HLA-A2402 binding peptide","volume":"166","author":"Inoue","year":"2001","journal-title":"J. Urol."},{"key":"10.1016\/j.canlet.2005.05.021_bib37","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/sj.bjc.6601642","article-title":"Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein prostein","volume":"90","author":"Kiessling","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2005.05.021_bib38","first-page":"1091","article-title":"Identification of naturally processed CD8 T cell epitopes from prostein, a prostate tissue-specific vaccine candidate, Eur","volume":"34","author":"Friedman","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2005.05.021_bib39","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1097\/01.ju.0000095151.97404.7c","article-title":"Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen","volume":"170","author":"Nanus","year":"2003","journal-title":"J. Urol."},{"key":"10.1016\/j.canlet.2005.05.021_bib40","first-page":"5807","article-title":"Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen","volume":"62","author":"Lu","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2005.05.021_bib41","doi-asserted-by":"crossref","first-page":"8365","DOI":"10.1158\/0008-5472.CAN-04-2146","article-title":"Evidence that TRPM8 is an androgen-dependent Ca2+ channel required for the survival of prostate cancer cells","volume":"64","author":"Zhang","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2005.05.021_bib42","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/pros.10265","article-title":"Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein trp-p8","volume":"56","author":"Kiessling","year":"2003","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2005.05.021_bib43","first-page":"221","article-title":"Multiple tumor marker analyses (PSA, hK2, PSCA trp-p8) in primary prostate cancers using quantitative RT-PCR","volume":"23","author":"Fuessel","year":"2003","journal-title":"Int. J. Oncol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438350500501X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438350500501X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T19:59:43Z","timestamp":1683143983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030438350500501X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S030438350500501X"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2005.05.021","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}